68_CD
Notes_NN
to_PIN
Group_NN
financial_JJ
statements_NOMZ
31_CD
DECEMBER_NN
2003_CD
29_CD
RELATED_VBN
PARTY_NN
TRANSACTIONS_NOMZ
Under_IN
the_DT
provisions_NN
of_PIN
FRS8_CD
,_,
Related_NN
Party_NN
Disclosures_NN
,_,
it_PIT
is_VPRT [BEMA]
not_XX0
necessary_PRED
to_TO
disclose_VB [PUBV]
related_JJ
party_NN
transactions_NOMZ
between_PIN
the_DT
Company_NN
,_,
Acambis_NN
Research_NN
Limited_NN
,_,
Acambis_NN
Inc._NN
._.
Smallpox_NN
Biosecurity_NOMZ
Limited_NN
and_PHC
Berna_NN
Products_NN
Corporation_NOMZ
because_CAUS
they_TPP3
are_VPRT [PASS]
eliminated_VBN
on_PIN
preparation_NOMZ
of_PIN
the_DT
Groups_NN
financial_JJ
statements_NOMZ
._.
As_IN
described_VBN
in_PIN
note_NN
21_CD
,_,
the_DT
Group_NN
has_VPRT
an_DT
interest_NN
in_PIN
the_DT
Joint_NN
Venture_NN
._.
Since_OSUB
May_POMD
1999_CD
,_,
Acambis_NN
has_VPRT [PEAS]
performed_VBN
a_DT
pre-agreed_JJ
work_NN
program_NN
on_PIN
behalf_NN
of_PIN
the_DT
Joint_NN
Venture_NN
._.
Costs_NN
incurred_VBN [WZPAST]
by_PIN
the_DT
Group_NN
on_PIN
behalf_NN
of_PIN
the_DT
Joint_NN
Venture_NN
and_CC
corresponding_JJ
turnover_NN
received_VBN [WZPAST]
from_PIN
the_DT
Joint_NN
Venture_NN
have_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
the_DT
Groups_NN
financial_JJ
statements_NOMZ
._.
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
,_,
the_DT
Group_NN
has_VPRT [PEAS]
included_VBN
turnover_NN
of_PIN
0.3_CD
m_NN [BEMA]
2002_CD
0.3_CD
m_NN [BEMA]
in_PIN
respect_NN
of_PIN
costs_NN
incurred_VBN [WZPAST]
in_PIN
performing_VBG
services_NN
for_PIN
the_DT
Joint_NN
Venture_NN
and_CC
a_DT
loss_NN
of_PIN
0.1_CD
m_NN [BEMA]
2002_CD
0.2_CD
m_NN [BEMA]
within_PIN
its_PIT
Group_NN
financial_JJ
statements_NOMZ
._.
At_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
amounts_NN
the_DT
Group_NN
owed_VBD
to_PIN
the_DT
Joint_NN
Venture_NN
amounted_VBD
to_TO
nil_VB
2002_CD
nil_NN
._.
Amounts_NN
owed_VBN [WZPAST]
by_PIN
the_DT
Joint_NN
Venture_NN
to_PIN
the_DT
Group_NN
at_PIN
31_CD
December_NN
2003_CD
were_VBD [BEMA]
nil_PRED
2002_CD
nil_NN
._.
In_PIN
2002_CD
,_,
the_DT
Group_NN
took_VBD
the_DT
view_NN
that_DEMP
,_,
taking_VBG [PRESP]
into_PIN
account_NN
the_DT
increase_NN
in_PIN
its_PIT
shareholding_GER
in_PIN
Acambis_NN
and_CC
the_DT
presence_NN
of_PIN
a_DT
representative_NN
from_PIN
Baxter_NN
on_PIN
the_DT
Board_NN
,_,
Baxters_NN
influence_NN
on_PIN
Acambis_NN
was_VBD [BEMA]
significant_PRED
,_,
and_ANDC
therefore_CONJ
Baxter_NN
was_VBD [BEMA]
a_DT
related_JJ
party_NN
for_PIN
the_DT
full_JJ
year_NN
._.
The_DT
Groups_NN
long-term_JJ
lease-finance_NN
facility_NOMZ
with_PIN
Baxter_NN
is_VPRT [PASS]
described_VBN
within_PIN
Financial_NN
liabilities_NOMZ
in_PIN
note_NN
22_CD
._.
The_DT
Group_NN
made_VBD
sales_NN
to_PIN
Baxter_NN
of_PIN
14.1_CD
m_NN [BEMA]
in_PIN
the_DT
year_NN
2002_CD
0.7_CD
m_NN [BEMA]
of_PIN
which_WDT [PIRE]
1.1_CD
m_NN [BEMA]
2002_CD
0.7_CD
m_NN [PASS]
was_VBD [PASS]
not_XX0
received_VBN
at_PIN
the_DT
year-end_NN
,_,
and_ANDC
made_VBD
purchases_NN
of_PIN
goods_NN
and_PHC
services_NN
from_PIN
Baxter_NN
of_PIN
50.4_CD
m_NN [BEMA]
2002_CD
45.7_CD
m_NN [BEMA]
of_PIN
which_WDT [PIRE]
9.4_CD
m_NN [BEMA]
2002_CD
42.7_CD
m_NN [PASS]
was_VBD [BEMA]
unpaid_PRED
at_PIN
the_DT
year-end_NN
._.
There_EX
were_VBD
no_SYNE
transactions_NOMZ
between_PIN
the_DT
Company_NN
and_PHC
BPC_NN
prior_RB
to_PIN
its_PIT
acquisition_NOMZ
._.
30_CD
POST_NN
BALANCE_NN
SHEET_NN
EVENTS_NN
In_PIN
January_NN
2004_CD
,_,
Acambis_NN
announced_VBD [PUBV]
the_DT
outcome_NN
of_PIN
a_DT
project_NN
prioritisation_NOMZ
review_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
an_DT
operational_JJ
review_NN
was_VBD [SPAU] [PASS]
also_RB
completed_VBN
and_CC
Acambis_NN
decided_VBD [SUAV] [PRIV]
to_TO
consolidate_VB
its_PIT
research_NN
activities_NOMZ
at_PIN
its_PIT
facility_NOMZ
in_PIN
Cambridge_NN
,_,
Massachusetts_NN
._.
The_DT
research_NN
operation_NOMZ
in_PIN
Cambridge_NN
,_,
UK_NN
will_PRMD
close_VB
during_PIN
2004_CD
._.
However_CONJ
,_,
Acambis_NN
is_VPRT
retaining_VBG
clinical_JJ
and_PHC
regulatory_JJ
functions_NOMZ
in_PIN
Cambridge_NN
,_,
UK_NN
,_,
as_RB
well_RB
as_IN
various_JJ
head_NN
office_NN
functions_NOMZ
and_PHC
sales_NN
,_,
marketing_GER
and_PHC
business_NOMZ
development_NOMZ
._.
Once_TIME
the_DT
operational_JJ
review_NN
is_VPRT [SPAU] [PASS]
fully_AMP
implemented_VBN
during_PIN
2004_CD
,_,
Acambis_NN
headcount_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
reduce_VB
by_PIN
around_PLACE
40_CD
to_PIN
around_PLACE
280_CD
worldwide_NN
._.
